Initial results of neoadjuvant chemotherapy on epithelial ovarian cancer figo iiic-iv at Hanoi Medical University Hospital
Main Article Content
Abstract
Objective of our study was carried out among 10 patients with stage IIIC-IV ovarian cancer who received preoperative chemotherapy with paclitaxel-carboplatin regimen at Hanoi Medical University Hospital from January 2020 to July 2021. The mean age was 60.5. There were 3 patients with stage IIIC, 7 patients with stage IV, and 4 patients with performance status score ECOG-2. There were 9 patients were operated after preoperative chemotherapy, and 1 patient who refused surgery. In terms of postoperative results, there were 8 patients responding with residual tumors < 1cm, 1 patient achieving response with residual tumors > 1cm after chemotherapy. Neutropenia was the most common side effect, accounting for 5/10 patients; leukopenia grade 3.4 was reported in 1 patient. Other side effects: anemia, vomiting/nausea, diarrhea, peripheral neurotoxicityoccur at the low rate and all were mild (degree 1,2). After surgery, 1 patient had a part obstructive complication; there was no evidence of other posoperative complications.
Article Details
Keywords
Ung thư buồng trứng giai đoạn IIIC-IV, hoá chất tiền phẫu.
References
2. Sung, H., Ferlay, J., Siegel, R. L. et al. Global cancer statistics: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: a cancer journal for clinicians. 2021; 71(3): 209-249 .
3. Gao, Zhang, Han et al. Evaluating the benefits of neoadjuvant chemotherapy for advanced epithelial ovarian cancer: a retrospective study. Journal of ovarian research. 2019; 12(1): 1-8.
4. Vergote, I., Tropé,Amant, F., Kristensen et al. Neoadjuvant chemotherapy or primary surgery in stage IIIC or IV ovarian cancer. New England Journal of Medicine, 2010;363(10): 943-953.
5. Phạm Thị Diệu Hà, Nhận xét giá trị của chất chỉ điểm u CA125 và HE4 trong chẩn đoán ung thư buồng trứng, Luận văn Thạc sĩ Y học, 2012; Trường Đại học Y Hà Nội.
6. Lee, Chung, Nam et al. Impact of increased utilization of neoadjuvant chemotherapy on survival in patients with advanced ovarian cancer: experience from a comprehensive cancer center. Journal of gynecologic oncology, 2018; 29(4).
7. Schwartz, Rutherford, Chambers et al. Neoadjuvant chemotherapy for advanced ovarian cancer: long-term survival. Gynecologic oncology. 1999; 72(1): 93-99.
8. Võ Văn Khoa, Nguyễn Vũ Quốc Huy. Nghiên cứu giá trị của HE4, CA-125, thuật toán nguy cơ ác tính buồng trứng (ROMA) trong chẩn đoán trước mổ ung thư buồng trứng. Tạp chí Phụ sản. 2018; 16(2): 79-85.
9. Van Der Burg ME, Van Lent M, Buyse M et al. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer. New England Journal of Medicine. 1995; 332(10): 629-634.
10. Look KY, Sandler A, Blessing J A et al. Phase II trial of gemcitabine as second-line chemotherapy of uterine leiomyosarcoma: a Gynecologic Oncology Group (GOG) Study. Gynecologic oncology. 2004; 92(2) 644-647.